Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma

被引：25
|
作者：
Rasi, G [1 ]
Terzoli, E
Izzo, F
Pierimarchi, P
Ranuzzi, M
Sinibaldi-Vallebona, P
Tuthill, C
Garaci, E
机构：
[1] CNR, Ist Med Sperimentale, I-00137 Rome, Italy
[2] Univ Rome Tor Vergata, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] SciClone Pharmaceut Inc, San Mateo, CA USA
来源：
MELANOMA RESEARCH | 2000年 / 10卷 / 02期
关键词：
advanced melanoma; combination treatment; DTIC; interferon; thymosin-alpha; 1;
D O I：
10.1097/00008390-200010020-00012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：189 / 192
页数：4
相关论文
共 50 条
  • [31] High-dose recombinant interferon-α1b: An effective immunotherapy with low toxicity for melanoma patients
    Liu, Y.
    Shi, Q.
    Zhao, Y.
    Zhu, G.
    Wang, L.
    Wang, G.
    Li, C.
    Gao, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S144 - S144
  • [32] Low-dose interferon-α treatment for feline immunodeficiency virus infection
    Pedretti, E
    Passeri, B
    Amadori, M
    Isola, P
    Di Pede, P
    Telera, A
    Vescovini, R
    Quintavalla, F
    Pistello, M
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2006, 109 (3-4) : 245 - 254
  • [33] High dose interferon-α-2b adjuvant treatment for melanoma:: The UK experience
    Katerinaki, E
    Kularatne, B
    Hambly, R
    Turner, L
    Hancock, BW
    Lorigan, P
    BRITISH JOURNAL OF CANCER, 2003, 88 : S66 - S66
  • [34] Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
    Lindnér, P
    Rizell, M
    Mattsson, J
    Hellstrand, K
    Naredi, P
    ANTICANCER RESEARCH, 2004, 24 (3B) : 1837 - 1842
  • [35] Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma
    Strojan, P
    Rudolf, Z
    MELANOMA RESEARCH, 1997, 7 (05) : 420 - 427
  • [36] Long term survival benefit after adjuvant treatment of high risk cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised, multicentre trial.
    Stadler, R
    Luger, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 714S - 714S
  • [37] Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma
    Kirchberger, Michael C.
    Hauschild, Axel
    Schuler, Gerold
    Heinzerling, Lucie
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 182 - 184
  • [38] Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation
    Petrovic, Ivan M.
    Koricanac, Lela B.
    Todorovic, Danijela V.
    Ristic-Fira, Aleksandra M.
    Valastro, Lucia M.
    Privitera, Giuseppe
    Cuttone, Giacomo
    SIGNAL TRANSDUCTION PATHWAYS, PT C: CELL SIGNALING IN HEALTH AND DISEASE, 2007, 1095 : 154 - 164
  • [39] Expression of pro-angiogenic factors in malignant melanoma and their regulation by low-dose interferon-α
    Go, M
    Biber, J
    Lesinski, GB
    Carson, WE
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : S122 - S122
  • [40] Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma
    Kan, Takanobu
    Takahagi, Shunsuke
    Kawai, Mikio
    Matsubara, Daiki
    Tanaka, Akio
    Hide, Michihiro
    JOURNAL OF DERMATOLOGY, 2020, 47 (08): : 907 - 910
12345